Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by FSD Pharma Inc.

< Previous 1 2 Next >
FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Announces Filing of Year-End 2022 Results
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Announces Share Repurchase Program
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Announces Changes to the Board of Directors
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
From FSD Pharma Inc.
Via Business Wire
Tickers CSE:HUGE HUGE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.